Views on Suven Pharma & Cohance Lifesciences Merger by Mr. Manmohan Tiwana, MD & CEO at Wodehouse Capital
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Below the Views on Suven Pharma & Cohance Lifesciences Merger by Mr. Manmohan Tiwana, MD & CEO at Wodehouse Capital
"Cohance Lifesciences being an integrated API and CDMO manufacturer with a strong vintage shall demonstrate strong synergies post its merger with Suven Pharma, a world-class manufacturer of pharmaceuticals and fine chemical intermediates. This merger will provide operational efficiences and end-to-end product development and delivery for the end-customer with strong raw material sourcing. This merger will create tremendous shareholder value. Also, merging synergistic privately owned companies with their publicly owned company provides private equity firms a clear path to exit."
Above views are of the author and not of the website kindly read disclaimer
Tag News
Weekly Market Analysis : Markets rebounded after two weeks of profit-taking and gained over ...
More News
US SEC approves bitcoin ETFs- Here is what industry experts shares
